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Background. Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is a rising public health threat since its first out-
breaks in New York City (NYC) in the early 2000s. We investigated annual trends of CRKP infection in hospital-acquired infections 
(HAIs) and community-onset infections (COIs) treated in 3 NYC hospitals from 2006 to 2014.
Methods. We extracted K pneumoniae infection data including carbapenem susceptibility and anatomical sites, compared clinical 
characteristics between CRKP and carbapenem-susceptible K pneumoniae infections, and determined CRKP infection proportions 
in total K pneumoniae infections in HAI and COI to identify statistically significant trends from 2006 to 2014 using the Cochran-
Armitage trend test.
Results. Carbapenem-resistant K pneumoniae contributed 17.3% (601 of 3477)  of hospital-acquired K pneumoniae infection 
compared with 7.7% (149 of 1926) in COI from 2006 to 2014. Carbapenem-resistant K pneumoniae proportions in HAI and COI 
were positively correlated over time (r = 0.83, P < .01), and there were downward annual trends of CRKP proportions from 2006 to 
2014 in both HAI and COI (25.8% to 10.5% in HAI, P < .001; 13.6% to 3.1% in COI, P < .001). By anatomical site, significant down-
ward annual trends were present only in urinary tract infection (P < .001 for both HAI and COI) from 2006 to 2014.
Conclusions. Annual trends of CRKP proportions from 2006 to 2014 were downward in both HAI and COI, and HAI and COI 
were positively correlated. Efforts to reduce and prevent CRKP infections in both hospital and community settings were successful 
and warrant continuation.
Keywords.  carbapenem-resistant Klebsiella pneumoniae (CRKP); carbapenem-susceptible Klebsiella pneumoniae (CSKP); com-
munity-onset infection (COI); hospital-acquired infection (HAI).
Carbapenems are considered the antibiotics of choice for Gram-
negative bacteria that produce plasmid-encoded extended-spec-
trum β-lactamases (ESBL) or chromosomal cephalosporinases 
[1]. Since imipenem became the first carbapenem available in 
1985, there have been no new classes of antibiotics targeting 
drug-resistant Gram-negative bacteria [2, 3]. During the past 
decade, carbapenem-resistant Enterobacteriaceae (CRE) have 
become a public health threat and economic burden due to lack of 
effective antibiotics, wide transmission, and high mortality rate of 
up to 50% in blood stream infections (BSIs) [4, 5]. Carbapenem-
resistant Enterobacteriaceae represent 1 of the 3 urgent antibiotic 
resistance threats ranked by the Centers for Disease Control 
and Prevention ([CDC] the other 2 are Clostridium difficile 
and drug-resistant Neisseria gonorrhoeae [http://www.cdc.gov/
drugresistance/threat-report-2013]). The most common mech-
anism for carbapenem resistance in CRE is production of car-
bapenemases [5, 6]. Carbapenemases are commonly expressed 
from mobile genetic elements such as plasmids or transposons, 
which frequently contain multiple drug-resistant genes and have 
the potential for widespread transmission to other bacteria via 
horizontal gene transfer [6, 7]. Carbapenem-resistant Klebsiella 
pneumoniae (CRKP) is one of the most commonly reported CRE 
in healthcare settings in the United States [8, 9].
Although K pneumoniae carbapenemase (KPC) was first iden-
tified in a K pneumoniae from a clinical specimen of a patient in 
North Carolina in 1996 [6, 10], CRKP was rarely reported until 
the early 2000s in the United States [11]. After the outbreaks of 
KPC-producing CRKP in New York City (NYC) hospitals in the 
early 2000s, KPC-producing CRKP has spread throughout the 
United States and worldwide [6, 7, 12–16]. Carbapenem-resistant 
K pneumoniae that produce other types of carbapenemases such 
as New Delhi metallo-β-lactamase (NDM) and oxacillinase-48 
have also been increasingly reported [6] (http://www.cdc.gov/
hai/organisms/cre/TrackingCRE.html). In 2000, less than 1% of 
Klebsiella isolates reported to the CDC were CRKP, the preva-
lence then increased to 8% in 2007 [17]. In 2009–2010, CRKP 
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proportions that were associated with certain device-related 
infections were greater than 12% according to a report from 
the National Healthcare Safety Network (NHSN) [9]. Within 
the past few years, CRKP proportions have been trending down 
according to the NHSN’s online report (http://gis.cdc.gov/grasp/
PSA/MapView.html); the percentage of carbapenem-resistant 
Klebsiella isolates decreased from 9.8% to 7.8% in the nation 
and 16.2% to 14.2% in New York state (NYS) from 2011 to 2014, 
based on the collected data for hospital-acquired infections 
(HAIs). Besides the national studies [8, 9, 18, 19] and short-term 
studies of CRKP in NYC hospitals [13, 14, 20], there is limited lit-
erature on temporal trends of CRKP in NYC hospitals. Literature 
is similarly limited regarding temporal trends of community-on-
set CRKP, and association between trends of CRKP in HAIs and 
in community-onset infections (COIs) has not been studied. 
Knowledge of temporal trends of CRKP in NYC hospitals is crit-
ical because (1) information of temporal trends would inform 
decisions for antimicrobial stewardship and infection control 
policymaking and (2) temporal trends of CRKP in NYC hospi-
tals would likely predict temporal trends in various other loca-
tions. Hence, we investigated annual CRKP proportions trends 
in HAI and COI treated in 3 NYC hospitals over a 9-year period 
(2006–2014) and their correlation in the same period. We also 
investigated annual CRKP proportions trends by anatomical sites 
(respiratory, urinary tract, bloodstream, and surgical site) and 
clinical characteristics of CRKP infections.
METHODS
Study Setting and Data Collection
We extracted data from a large healthcare system in NYC, 
which includes a community hospital, a pediatric hospital, 
and a tertiary care hospital totaling 575 373 admissions in 
2006−2014. The 3 hospitals share a clinical data warehouse that 
integrates data from over 20 clinical electronic sources [21]. The 
data included the following: (1) patients’ locations, prior hos-
pitalization, length of stay, and admission source; (2) patients’ 
comorbid conditions including dementia, diabetes, malignancy, 
acquired immune deficiency syndrome, cardiac, cerebrovascu-
lar, liver, kidney, and pulmonary disease (to calculate a weighted 
Charlson Comorbidity Index); (3) accounts of administered 
antibiotics; and (4) results of microbiologic tests.
Case Definitions and Study Subjects
As part of an National Institutes of Health-funded project 
(5R01NR010822), whose methods were described in Apte et  al 
[21], a team of clinicians and researchers developed electronic 
algorithms to define BSI, urinary tract infection (UTI), pneumo-
nia (PNU), surgical site infection (SSI), the causative organisms, 
and antibiotic susceptibility. Surgical site infection was defined 
using the surveillance definition from the CDC’s NHSN [21]. 
We defined COI as an infection that occurred before or on the 
3rd hospital day without being admitted from another healthcare 
setting and without history of admission to one of the study hos-
pitals within the previous 30  days, and we defined HAI as an 
infection that occurred after the 3rd hospital day or occurred in 
persons who were admitted from another healthcare setting or 
admitted to one of the study hospitals within the previous 30 days.
One microbiology laboratory processed all clinical speci-
mens and performed carbapenem susceptibility tests primar-
ily by Vitek 2 (bioMérieux Inc., Durham, NC). When Etest 
(bioMérieux Inc.) for meropenem or imipenem was also per-
formed (usually upon a clinician’s request or due to a discrepancy 
in susceptibilities between carbapenems by Vitek 2), the result of 
Etest was used over Vitek 2 to determine carbapenem suscep-
tibilities. The microbiology laboratory used the latest Clinical 
Laboratory Standards Institute (CLSI) interpretive criteria and 
adopted the revised (June 2010)  CLSI interpretive criteria for 
Enterobacteriaceae in January 2011. We categorized the labora-
tory reports of imipenem- or meropenem-susceptible as carbap-
enem-susceptible, and we categorized reports of imipenem- or 
meropenem-resistant or -intermediate as carbapenem-resistant. 
When there was a discrepant report on susceptibility test for 
imipenem and meropenem (imipenem was susceptible but mer-
openem was resistant, or vice versa), we categorized it as resist-
ant. Study subjects were patients with K pneumoniae infection 
in 1 of 4 anatomical sites, BSI, UTI, PNU, or SSI in 2006−2014. 
Each patient was eligible only once. If K pneumoniae was isolated 
from multiple anatomical sites either through 1 hospitalization 
or multiple hospitalizations, only the first infection was counted.
Measures
We measured annual CRKP proportions (cases of CRKP infec-
tion divided by cases of K pneumoniae [KP] infection and mul-
tiplied by 100) at each of the 4 anatomical sites of infection (BSI, 
UTI, PNU, and SSI). Overall, CRKP proportions combined the 
above 4 sites. Carbapenem-resistant K pneumoniae propor-
tions (HAI and COI) of the 3 individual hospitals and 3 hospi-
tals combined were examined from 2006 to 2014 annually. We 
measured differences in various clinical characteristics between 
CRKP and CSKP (Table 1) and the strength of linear associa-
tions between CRKP proportions in HAI and COI.
Statistical Analysis
To compare clinical characteristics between CRKP and CSKP, 
we performed bivariate analyses using χ2 test for categorical 
variables and Student t test or Wilcoxon rank-sum test for 
continuous variables, dependent on the validity of normal-
ity assumption. We performed multiple logistic regression to 
determine associations between CRKP proportions and vari-
ables that were statistically significant from bivariate analyses.
We used Cochran-Armitage trend test [18] to determine 
statistical significance in annual CRKP proportions trends 
and used Pearson’s correlation coefficient, r, to indicate linear 
associations between HAI and COI CRKP proportions. We 
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Table 1 shows clinical characteristics of patients who were hospi-
talized at one of the study institutions with K pneumoniae infec-
tion in 2006−2014. Mean age was older in COI compared with 
HAI (65.5 vs 61.7 years, P < .01). Females contributed 54.9% (330 
of 601) of CRKP in HAI and 53.0% of CRKP in COI, but they 
had smaller CRKP proportions compared with males (females 
16.8% vs males 18.0% in HAI; 6.1% vs 11.2% in COI) because 
female KP infection population was larger than male’s (Table1).
In bivariate analyses of HAI, the anatomical site was sig-
nificantly associated with CRKP infection; the odds of CRKP 
infection in PNU is greater than the odds of CRKP infection in 
BSI (the odds ratio [OR] = 2.0, P < .01) and in UTI (OR = 1.60, 
P  <  .01). In bivariate analyses of HAI, CRKP infection was 
positively associated with dialysis status (OR = 2.64, P < .001), 
longer hospital stay (OR = 1.01, P <  .001), intensive care unit 
(ICU) stay (OR = 1.58, P < .001), longer ICU days (OR = 1.01, 
P < .001), and antibiotic use (OR = 2.04, P < .001), whereas it was 
negatively associated with history of malignancy (OR  =  0.69, 
P < .01) (Table 1). In multivariable analysis of HAI, dialysis sta-
tus, longer hospital stay, and antibiotic use were independently 
positively associated, whereas history of malignancy was inde-
pendently negatively associated with CRKP infection (Table 2).
Table 1. Clinical Characteristics of Patients With Carbapenem-Resistant vs Carbapenem-Susceptible Klebsiella pneumonia in Hospital-Acquired and 
Community-Onset Infections
Characteristics
Hospital-Acquired Infection (n = 3477) Community-Onset Infection (n = 1926)
CRKP (n = 601) CSKP (n = 2876) P Value CRKP (n = 149) CSKP (n = 1777) P Value
Age (year), mean ± SD 62.3 ± 20.0 61.6 ± 24.1 .24 68.5 ± 17.7 65.2 ± 22.4 0.31
Female sex 330 (54.9) 1639 (57.0) .35 79 (53.0) 1220 (68.7) <.001
Hospital <.001a .09a
1 (tertiary) 466 (77.5) 2134 (74.2) 106 (71.1) 1234 (69.4)
2 (community) 112 (18.6) 430 (15.0) 40 (26.9) 429 (24.1)
3 (children’s) 23 (3.8) 312 (10.8) 3 (2.0) 114 (6.4)
Anatomical site <.001a .12a
 UTI 372 (61.9) 1897 (66.0) 124(83.2) 1448 (81.5)
 PNU 148 (24.6) 473 (16.4) 13(8.7) 104 (5.8)
 BSI 66 (11.0) 421 (14.6) 12(8.1) 225 (12.7)
 SSI 15 (2.5) 85 (3.0)
Year of infection <.001a <.001a
 2006 102 (17.0) 294 (10.2) 30 (20.1) 190 (10.7)
 2007 101 (16.8) 308 (10.7) 35 (23.5) 224 (12.6)
 2008 89 (14.8) 283 (9.8) 29 (19.5) 165 (9.3)
 2009 62 (10.3) 390 (13.6) 16 (10.7) 237 (13.3)
 2010 40 (6.7) 355 (12.3) 16 (10.7) 220 (12.4)
 2011 48 (8.0) 236 (8.2) 4 (2.7) 122 (6.9)
 2012 49 (8.2) 333 (11.6) 5 (3.4) 185 (10.4)
 2013 72 (12.0) 352 (12.2) 7 (4.7) 216 (12.2)
 2014 38 (6.3) 325 (11.3) 7 (4.7) 218 (12.3)
Diabetes 201 (33.4) 880 (30.6) .17 46 (30.9) 612 (34.5) .38
Malignancy 93 (15.5) 602 (20.9) <.01 23 (15.4) 258 (14.5) .76
Dialysis 91 (15.1) 182 (6.3) <.001 6 (4.0) 64 (3.6) .79
History of transplant 28 (4.7) 123 (4.3) .68 8 (5.4) 71 (4.0) .42
Charlson Comorbidity Index, mean ± SD 2.9 ± 2.4 2.9 ± 2.6 .46 2.6 ± 2.5 2.5 ± 2.4 .22
Prior hospitalizationb 348 (57.9) 1743 (60.6) .22 69 (46.3) 979 (55.1) .04
Hospital LOS before KP infection, mean ± SD 13.7 ± 18.7 9.7 ± 15.2 <.001 N/A N/A N/A
ICU stay before KP infection 261 (43.4) 939 (32.7) <.001 N/A N/A N/A
ICU days before KP infection, mean ± SD 14.9 ± 18.2 10.7 ± 16.3 <.001 N/A N/A N/A
Antibiotics before KP infectionc 382 (63.6) 1325 (46.1) <.001 N/K N/K N/K
Abbreviations: BSI, blood stream infection; CRKP, carbapenem-resistant K pneumoniae; CSKP, carbapenem-susceptible K pneumoniae; ICU, intensive care unit; LOS, length of stay; N/A, not 
applicable; N/K, not known; PNU, pneumonia; SD, standard deviation; SSI, surgical site infection; UTI, urinary tract infection.
Note: Data are No. (%), unless indicated. P values were obtained from bivariate analyses.
aOverall P value for a variable with multiple categories.
bPrior hospitalization at the study in New York City hospitals.
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In bivariate analyses of COI, CRKP infection was positively 
associated with male sex (OR = 1.94, P <  .01), whereas it was 
negatively associated with prior hospitalization (OR  =  0.70, 
P =  .04) (Table 1). In multivariable analysis of COI, male sex 
was independently positively associated with CRKP infection. 
In both HAI and COI, data year was independently associated 
with CRKP infection (Table 2).
Downward Trends of Carbapenem-Resistant Klebsiella pneumoniae 
In 2006−2014, 17.3% of total K pneumoniae in HAI and 7.7% 
of total K pneumoniae in COI was CRKP. There were down-
ward annual CRKP proportions trends in both HAI (from 
25.8% to 10.5%) and COI (from 13.6% to 3.1%) from 2006 
to 2014 (Figure  1). Furthermore, downward annual CRKP 
proportions trends were found in each study hospital from 
2006 to 2014 in both HAI (from 27.8% to 12.2% in Hospital 
1; from 32.9% to 4.8% in Hospital 2; from 8.3% to 0.0% in 
Hospital 3) and COI (from 11.8% to 4.2% in Hospital 1; from 
19.7% to 1.6% in Hospital 2; from 6.7% to 0.0% in Hospital 
3) (Figure S1).
In HAI, PNU had the highest CRKP proportions followed by 
UTI, SSI, and BSI (23.8%, 16.4%, 15%, 13.6%, respectively), simi-
larly in COI, PNU had the highest CRKP proportions followed by 
UTI and BSI (11.1%, 7.9%, 5.1%, respectively). Downward CRKP 
proportions trends in UTI were significant in both HAI (from 
25.1% to 8.3%) and COI (from 15.2% to 2.6%) in 2006−2014 
(Figure 2). There were no statistically significant CRKP propor-
tions trends in BSI and PNU in either HAI or COI in 2006–2014 
(Figure  2). There were no cases of CRKP in SSI from 2006 to 
2011, but significant upward CRKP proportion trends were iden-
tified from 2011 to 2014 (from 0% to 18.2%; P = .03).
Hospital-acquired infections and COI CRKP proportions 
were positively correlated in 2006–2014 (r = 0.83, P < .01). In 
2006–2014, there was significant positive correlation between 
Table 2. Multivariable Analyses for Carbapenem-Resistant vs Carbapenem-Susceptible Klebsiella pneumoniae in Hospital-Acquired and Community-
Onset Infections
Characteristics
Hospital-Acquired Infection Community-Onset Infection
Multivariable Multivariable
CRKP vs CSKP CRKP vs CSKP
Variables OR (95% CI) P Value OR (95% CI) P Value
Sex (male vs female) N/A N/A 2.11 (1.50− 3.00) <.001
Prior hospitalization N/A N/A 0.89 (0.63–1.27) .53
Year of infection <.001a <.001a
 2006 1 1
 2007 0.89 (0.64−1.24) 1.04 (0.61−1.78)
 2008 0.86 (0.61−1.21) 1.14 (0.65− 2.01)
 2009 0.42 (0.29−0.61) 0.44 (0.23− 0.83)
 2010 0.31 (0.21−0.47) 0.47 (0.25−0.91)
 2011 0.55 (0.37−0.82) 0.23 (0.08−0.67)
 2012 0.41 (0.28−0.61) 0.16 (0.06−0.44)
 2013 0.54 (0.38−0.78) 0.20 (0.09−0.48)
 2014 0.31 (0.21−0.47) 0.21 (0.09−0.49)
Hospital <.001a N/A
1 (tertiary) 1 N/A
2 (community) 1.45 (1.14−1.88) N/A
3 (children’s) 0.29 (0.19−0.47) N/A
Anatomical site .65a N/A
 UTI 1 N/A
 PNU 1.10 (0.86−1.41) N/A
 BSI 0.89 (0.66−1.20) N/A
 SSI 1.14 (0.63−2.06) N/A
Malignancy 0.72 (0.56−0.93) .01 N/A N/A
Dialysis 1.87 (1.39−2.50) <.001 N/A N/A
Hospital LOS before KP infection 1.01 (1.003−1.02) <.01 N/A N/A
ICU stay before KP infection 1.004 (0.80–1.30) .97 N/A N/A
Antibiotics before KP infection 1.84 (1.46−2.32) <.001 N/A N/A
Abbreviations; BSI, blood stream infection; CI, confidence interval; CRKP, carbapenem-resistant K pneumoniae; CSKP, carbapenem-susceptible K pneumoniae; ICU, intensive care unit; KP, 
K pneumoniae; LOS, length of stay; N/A, not applicable; OR, odds ratio; PNU, pneumonia; SSI, surgical site infection; UTI, urinary tract infection.
Note: Multivariable analyses included variables with statistical significance (P < .05) from the Table 1.
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CRKP proportions in UTIs in HAI and COI (r = 0.87, P < .01), 
but no significant correlations between CRKP proportions in 
BSIs in HAI and COI (r = 0.08, P =  .83), and between CRKP 
proportions in PNUs in HAI and COI (r = 0.25, P = .52). There 
were significant positive correlations between CRKP propor-
tions in BSI and PNU (r = 0.80, P = .01), UTI and PNU (r = 0.70, 
P = .04), but no significant correlation between CRKP propor-
tions in BSI and UTI (r = 0.60, P = .09) in HAI. There were no 
significant correlations between CRKP proportions in BSI and 
PNU (r = −0.17, P = .67), UTI and PNU (r = 0.59, P = .09), and 
BSI and UTI (r = 0.27, P = .50) in COI.
DISCUSSION
Carbapenem-Resistant Klebsiella pneumoniae Proportions in Hospitals 
and Community Settings Are Positively Correlated
Klebsiella pneumoniae is a normal intestinal flora in humans 
and animals and a common microorganism in the environment, 
which can become carbapenem-resistant by acquiring genes 
coding for carbapenemase, or loss of outer membrane porin con-
currently with ESBL or AmpC β-lactamase production [1]. In 
the United States, majority of dissemination of KPC-producing 
CRKP is clonal with a common strain type, ST258 [6, 10, 11].
Carbapenem-resistant K pneumoniae infections have been 
predominantly reported in healthcare settings such as acute 
care hospitals, long-term acute care hospitals (LTACHs), and 
nursing homes [10, 19, 22], where broader spectrum antibiot-
ics are used for longer duration [23] and odds of contacts with 
CRKP are higher. Furthermore, LTACHs and nursing homes 
have been known to be major reservoirs in dissemination of 
CRKP in multiple regions, where populations with complex 
comorbidities require prolonged care [24, 25]. Our study sup-
ports the conventional knowledge that CRKP is more prevalent 
in the hospital settings than in the community settings. We note 
that CRKP proportion in COI (mean 7.7%, range 2.6%−14.9%) 
is unlikely explained alone by personal use of antibiotics; other 
mechanisms such as person-to-person transmission must have 
played an important role.
Our findings indicate that overall CRKP proportions in HAI 
and COI are positively correlated in 2006–2014, whereas CRKP 
UTIs were the only anatomic sites infections that were signifi-
cantly correlated. It is possible that our study did not have the 
statistical power to detect correlations between CRKP propor-
tions of BSIs or PNUs in HAI and COI because of small sample 
sizes of CRKP in COI.
Antibiotic Use in Food Animals Could Contribute to  
Drug-Resistance Pattern
Antibiotic use selects for preexisting resistant populations of bac-
teria in nature [26]. Eighty percent of all antibiotics used in the 
United States are administered to food animals [2]. Subtherapeutic 
levels of antibiotics are frequently administered for infection 
prophylaxis or growth promotion, which are believed to promote 
drug resistance [27]. A direct correlation between drug-resistant 
bacteria in farm animals and their colonization or infection in 
humans has been reported [28]. Ninety percent of antibiotics 
given to animals are released in excreta and widely dispersed 
[2], potentially facilitating emergence of drug-resistant bacteria 
in our environment. As examples, NDM-producing bacteria was 
detected in drinking water (2 of 50 samples) and seepage water 
(51 of 171 samples) in New Delhi [29], and KPC-producing 
Escherichia coli was recovered from river water (1 of 5 samples), 
despite the fact that there were no prior reported cases of KPC-
producing bacteria in Portugal [10]. Although we have not found 
similar studies for CRE in NYC, ampicillin- or tetracycline-re-
sistant bacteria including Enterobacteriaceae were detected at all 
10 sampling sites around NYC and throughout the lower Hudson 
River Estuary in 2010 [30].
Figure 1. Trend analyses of annual carbapenem-resistant Klebsiella pneumoniae (CRKP) proportions. Carbapenem-resistant K pneumoniae proportions (CRKP infections/K 
pneumoniae [KP] infections) and total case numbers of KP infections are presented annually from 2006 to 2014 as marked. Downward CRKP proportions trends and the 
corresponding P values in hospital-acquired infection (HAI) and community-onset infection (COI), as indicated, were determined by Cochran-Armitage trend test. Trends with 
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Carriage of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Might 
Affect CRKP Prevalence
Asymptomatic carriage of CRKP silently transmits pathogens 
and increases risk for subsequent symptomatic infections [31]. 
Hence, knowledge in prevalence and duration of CRKP carriage 
is important to predict trends of CRKP infection and control. 
Surveillance rectal swab cultures were positive for CRKP in 
15.3% of 301 asymptomatic residents in a long-term care facility 
in NYC [31]. A retrospective cohort study from a tertiary med-
ical center in Israel described that the carrier status persisted 
for 2 years in 15% of 163 CRKP carriers [32]. Although studies 
regarding prevalence of CRKP carriage in the community set-
tings are limited, reports of high prevalence of drug-resistant 
E coli carriage in community settings where there were popu-
lations without previous antibiotic exposure [33, 34] raise the 
possibility of high prevalence of CRKP carriage in the com-
munity as well. Some of the patients in our study who rarely 
received antibiotics before CRKP infection might have acquired 
CRKP from carriers in the community.
Existing Knowledge of Carbapenem-Resistant Klebsiella pneumoniae 
Proportion and Prevalence in New York City Hospitals and Infection 
Control Efforts
Defining whether there are trends in CRKP infection is a prereq-
uisite to understanding the epidemiology of CRKP. Carbapenem-
resistant K pneumoniaes are distributed heterogeneously in the 
Figure 2. Annual carbapenem-resistant Klebsiella pneumoniae (CRKP) proportions trend analyses for various anatomical sites. Carbapenem-resistant K pneumoniae proportions 
(CRKP infections/K pneumoniae [KP] infections) and total case numbers of KP infections in 4 anatomical sites, as marked, are presented annually from 2006 to 2014. Upward or 
downward CRKP proportions trends and the corresponding P values in hospital-acquired infection (HAI) and community-onset infection (COI), as indicated, were determined by 
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United States, and most states (48 of 50 states; https://www.cdc.
gov/hai/organisms/cre/TrackingCRE.html) reported cases of 
CRKP infection [6].
In NYC, CRKP proportion was 1.5% (9 of 602 isolates) in 
a study involving 11 hospital-based microbiology labora-
tories in Brooklyn conducted in 2002−2003 [13]. In 2004, 4 
hospitals in Brooklyn found that 24% (62 of 257 isolates) of 
K pneumoniae isolates were KPC producers [14]. Surveillance 
studies conducted for a 3-month period in 2006 and 2009 in 
14 hospitals in Brooklyn showed a decline in proportions of 
KPC-producing K pneumoniae from 38% (302 of 1024 isolates) 
in 2006 to 29% (379 of 997 isolates) in 2009 [20, 35]. Active 
surveillance testing of perianal swab culture and clinical cul-
ture at a tertiary hospital in Manhattan in 2005−2007 showed 
that CRKP prevalence was 2% (215 of 11 236 patients) in study 
ICUs [36]. Active surveillance testing at 2 tertiary hospitals in 
Manhattan in 2009−2010 showed that CRE prevalence (84.7% 
was K pneumoniae) was 5.4% (306 of 5676 patients) in study 
inpatient units [23].
Literature and national reports showed sharp increases of 
CRKP proportions in 2000s [6, 11, 22], then slight decreases in 
2011−2014 (http://gis.cdc.gov/grasp/PSA/MapView.html). Our 
results indicate downward annual CRKP proportions trends in 
both HAI and COI in 2006−2014. Decreasing CRKP propor-
tions trends were sturdier in COI than in HAI. Trends in CRKP 
proportions of HAIs fluctuated in 2011−2014 after significant 
decreasing trends in 2006−2010.
Several factors could have affected the results of trends analy-
ses. First, we considered the possibility that breakpoint changes 
on carbapenem susceptibility for K pneumoniae affected our 
trends analyses. Because some carbapenemase-producing K 
pneumoniae were susceptible to carbapenems, the CLSI in June 
2010 lowered carbapenem breakpoints to capture all carbapene-
mase producers without the use of the Modified Hodge test [11, 
37]. The literature suggests that the percentage change of CRKP 
proportions after the CLSI breakpoint changes was less than 1% 
[37, 38]. Thus, it is unlikely that the revision of the CLSI inter-
pretive criteria significantly affected our results. Second, infec-
tion control efforts at the local and national level might have 
contributed to decreases in CRKP proportions. In 2012, the 
CDC introduced a CRE Toolkit as guidance for control of CRE, 
which was associated with a reduction in the incidence rate of 
CRE [39]. In April 2012, the US Food and Drug Administration 
issued a guidance to phase out unsupervised use of medically 
important antimicrobial drugs in food-producing animals, fol-
lowed by a guidance in December 2013 for voluntary removal of 
growth enhancement as an indication for antibiotic use (www.
fda.gov). In NYS, CRE became a statewide reportable condition 
on July 1, 2013 (www.apic.org), which has encouraged hospitals 
to proactively control CRE. Our study hospitals used an antimi-
crobial stewardship program since 2000 [40] and have a robust 
infection prevention and control program that implements 
staff education, bundled interventions, and isolation protocol. 
Whether these proactive steps can explain the downward trends 
of CRKP requires further studies.
Limitations
There are several limitations, which should be consid-
ered when interpreting our findings. (1) We retrospectively 
obtained our data from electronic databases, which has a 
limitation in differentiating between colonization and clin-
ical infection. (2) Due to lack of data from outside of the 
study hospitals, patients who were admitted within 30  days 
of discharge or surgical procedures performed outside of 
the study hospitals would have been misclassified as COI 
or not counted for SSI. (3) Microbiology laboratory did not 
routinely report or check ertapenem or doripenem suscepti-
bility, so ertapenem- or doripenem-resistant K pneumoniae 
might have been misclassified as carbapenem-susceptible. (4) 
Information regarding the mechanisms of carbapenem-re-
sistance is not available, limiting the depth of our analyses 
of CRKP infections. (5) NYC, the largest metropolitan in the 
nation, has a dense population that share environments such 
as public transportation that are different from many other 
parts in the United States. Therefore, our findings might not 
apply to other hospitals in less populated cities. Whether our 
findings are applicable to other hospitals in NYC also awaits 
further study.
CONCLUSIONS
In summary, we show that CRKP proportions trends in HAI 
and COI are positively and statistically significantly associated. 
We further present evidence for downward CRKP proportions 
trends in HAI and COI in 3 NYC hospitals. To extend these 
downward trends, judicious antibiotic use and infection con-
trol efforts should be continued in both hospital and commu-
nity settings. Higher CRKP proportions in HAI compared with 
COI in 2006−2014 warrant enhanced efforts to control CRKP 
in hospitals. Lastly, studies to understand and reduce CRKP 
carriage are indicated to enlighten the epidemiology of CRKP 
infections.
Supplementary Data
Supplementary material is available at Open Forum Infectious Diseases online.
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